Peptide Inhibitors Targeting Raf Kinase Dimerization Interface
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for tumors with mutant RAF kinases and RAS enzymes are limited due to drug resistance and heterogeneity, with existing inhibitors failing to effectively target mutant forms of these proteins, leading to unmet medical needs for improved treatment options.
Innovation Solution
Development of peptides that display a binding affinity for the dimer interface of Raf kinase proteins, specifically modifying the dimerization process to inhibit Raf kinase activity, thereby reducing tumor growth by delivering these peptides to tumor cells.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If ATP-competitive Raf inhibitors are used to treat RAS mutant tumors, then Raf kinase activity is inhibited, but paradoxical ERK activation occurs leading to treatment failure
Solution Approach 1:
The invention extracts and targets the specific dimerization interface of Raf kinases as a separate functional element from the ATP-binding site. By designing peptides that specifically bind to the dimerization interface (taking out this function), the patent prevents the harmful paradoxical activation mechanism while avoiding the limitation of ATP-competitive inhibitors that fail in RAS mutant tumors.
Solution Approach 2:
The patent introduces peptide inhibitors as intermediary molecules that mediate between the harmful dimerization process and the desired therapeutic outcome. These peptides act as mediators that specifically block the dimerization interface, preventing the formation of active Raf dimers that cause paradoxical ERK activation, thereby resolving the contradiction without affecting ATP binding.
2Reliability
If existing Raf inhibitors are used, then some Raf kinase activity is blocked, but they fail to effectively target mutant forms of the proteins due to drug resistance
Solution Approach 1:
The invention applies local quality by designing peptides with specific sequences that match the dimerization interface of Raf kinases. This localized approach targets the conserved dimerization interface structure rather than attempting to inhibit the variable ATP-binding sites that differ between wild-type and mutant forms, thereby achieving both reliability and adaptability to mutant forms.
3Ease of operation
If single drug treatments are used, then treatment simplicity is maintained, but drug resistance and tumor cell heterogeneity reduce treatment efficacy
Solution Approach 1:
The peptide inhibitors target the conserved dimerization interface that is common across different Raf kinase isoforms and mutant forms. This universal target approach allows a single peptide design to potentially address multiple tumor types and mutant forms (B-Raf V600E, non-V600E mutants, A-Raf, C-Raf), providing multi-functionality that overcomes heterogeneity and resistance while maintaining relative treatment simplicity.
Data Source
AI summary
Herein are described peptide-based compositions for modifying Raf kinase protein Dimerization. These compositions, treatments, and methods of use are directed to peptides that display a binding affinity for the dimer interface of a Raf kinase protein, methods for modifying Raf kinase dimerization, and methods for inhibiting tumor growth. An embodiment of the disclosure is a peptide generated by modifying an ordered sequence chosen from SEQ ID NO: 1 which corresponds to amino acids 503-521 of B-Raf kinase. The peptides disclosed herein include a modification to an ordered sequence of amino acids derived from SEQ ID NO: 1 that can improve or otherwise alter binding affinity of the peptide to the dimer interface.